News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Roche Holding AG Seeks to Broaden Use of Cancer Drug MabThera
March 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Swiss drugmaker Roche Holding AG (ROG.VX) is looking to broaden the use of its cancer drug MabThera in non-Hodgkin's lymphoma in Europe, underscoring the strength of its position in oncology.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
FDA
FDA Went Against Adcomm Votes More, Held Fewer Meetings in 2025
January 6, 2026
·
3 min read
·
Heather McKenzie
Opinion
Addressing the Regulatory Reality of Replacing
In Vivo
Models in Drug Development
January 5, 2026
·
6 min read
·
Xiaoxia Li
Drug pricing
Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure
January 2, 2026
·
2 min read
·
Nick Paul Taylor
Approvals
Vanda Ends 40-Year Motion Sickness Drug Drought With FDA Approval for Nereus
January 2, 2026
·
3 min read
·
Nick Paul Taylor
